{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:59:57Z","timestamp":1792929597549,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T00:00:00Z","timestamp":1597795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Estonian Research Foundation","award":["IUT34-5"],"award-info":[{"award-number":["IUT34-5"]}]},{"name":"Estonian Research Foundation","award":["PUT PRG685"],"award-info":[{"award-number":["PUT PRG685"]}]},{"name":"Estonian Research Foundation","award":["PUT PRG685"],"award-info":[{"award-number":["PUT PRG685"]}]},{"name":"Estonian Research Foundation","award":["PUT PRG685"],"award-info":[{"award-number":["PUT PRG685"]}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","award":["Project no. 2014-2020.4.01.15-0012"],"award-info":[{"award-number":["Project no. 2014-2020.4.01.15-0012"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The primary objective of this study was to evaluate how schizophrenia (SCH) spectrum disorders and applied antipsychotic (AP) treatment affect serum level of amino acids (AAs) and biogenic amines (BAs) in the early course of the disorder. We measured 21 different AAs and 10 BAs in a sample of antipsychotic (AP)-na\u00efve first-episode psychosis (FEP) patients (n\u2009=\u200952) at baseline, after 0.6-year as well as after 5.1-year treatment compared to control subjects (CSs, n\u2009=\u200937). Serum levels of metabolites were determined with AbsoluteIDQ p180 kit using flow injection analysis tandem mass spectrometry and liquid chromatography technique. Elevated level of taurine and reduced level of proline and alpha-aminoadipic acid (alpha-AAA) were established as metabolites with significant change in AP-na\u00efve FEP patients compared to CSs. The following 0.6-year treatment restored these alterations. However, further continuous 5.1-year AP treatment changed the metabolic profile substantially. Significantly elevated levels of asparagine, glutamine, methionine, ornithine and taurine, alongside with decreased levels of aspartate, glutamate and alpha-AAA were observed in the patient group compared to CSs. These biomolecule profile alterations provide further insights into the pathophysiology of SCH spectrum disorders and broaden our understanding of the impact of AP treatment in the early stages of the disease.<\/jats:p>","DOI":"10.1038\/s41598-020-71014-w","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T06:03:35Z","timestamp":1597817015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease"],"prefix":"10.1038","volume":"10","author":[{"given":"Madis","family":"Parksepp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisa","family":"Leppik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadri","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e4rt","family":"Uppin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Kangro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liina","family":"Haring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Vasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihkel","family":"Zilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,19]]},"reference":[{"key":"71014_CR1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0006-3223(01)01303-8","volume":"50","author":"JA Lieberman","year":"2001","unstructured":"Lieberman, J. A. et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 50, 884\u2013897 (2001).","journal-title":"Biol. Psychiatry"},{"key":"71014_CR2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41537-018-0063-7","volume":"4","author":"R Newton","year":"2018","unstructured":"Newton, R. et al. Diverse definitions of the early course of schizophrenia\u2014a targeted literature review. Npj Schizophr. 4, 21 (2018).","journal-title":"Npj Schizophr."},{"key":"71014_CR3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.psc.2007.04.010","volume":"30","author":"PJ Weiden","year":"2007","unstructured":"Weiden, P. J., Buckley, P. F. & Grody, M. Understanding and treating \u201cfirst-episode\u201d schizophrenia. Psychiatr. Clin. North Am. 30, 481\u2013510 (2007).","journal-title":"Psychiatr. Clin. North Am."},{"key":"71014_CR4","unstructured":"Lehman, A. F. et al. Practice guideline for the treatment of patients with schizophrenia, Second edition (2010)."},{"key":"71014_CR5","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00216-012-6117-1","volume":"404","author":"A Zhang","year":"2012","unstructured":"Zhang, A., Sun, H. & Wang, X. Serum metabolomics as a novel diagnostic approach for disease: a systematic review. Anal. Bioanal. Chem. 404, 1239\u20131245 (2012).","journal-title":"Anal. Bioanal. Chem."},{"key":"71014_CR6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.schres.2017.09.021","volume":"195","author":"J Davison","year":"2018","unstructured":"Davison, J., O\u2019Gorman, A., Brennan, L. & Cotter, D. R. A systematic review of metabolite biomarkers of schizophrenia. Schizophr. Res. 195, 32\u201350 (2018).","journal-title":"Schizophr. Res."},{"key":"71014_CR7","first-page":"63","volume":"11","author":"S Saleem","year":"2017","unstructured":"Saleem, S., Shaukat, F., Gul, A., Arooj, M. & Malik, A. Potential role of amino acids in pathogenesis of schizophrenia. Int. J. Health Sci. 11, 63\u201368 (2017).","journal-title":"Int. J. Health Sci."},{"key":"71014_CR8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-319-45096-4_5","volume-title":"The glutamate\/GABA-glutamine cycle","author":"ME Conway","year":"2016","unstructured":"Conway, M. E. & Hutson, S. M. BCAA metabolism and NH3 homeostasis. In The glutamate\/GABA-glutamine cycle (eds Schousboe, A. & Sonnewald, U.) 99\u2013132 (Springer, Berlin, 2016)."},{"key":"71014_CR9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/gm233","volume":"3","author":"M Ore\u0161i\u010d","year":"2011","unstructured":"Ore\u0161i\u010d, M. et al. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med. 3, 19 (2011).","journal-title":"Genome Med."},{"key":"71014_CR10","first-page":"1","volume":"21","author":"B Cao","year":"2019","unstructured":"Cao, B. et al. Metabolic profiling for water-soluble metabolites in patients with schizophrenia and healthy controls in a Chinese population: a case-control study. World J. Biol. Psychiatry 21, 1\u201311 (2019).","journal-title":"World J. Biol. Psychiatry"},{"key":"71014_CR11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fpsyt.2018.00155","volume":"9","author":"L Leppik","year":"2018","unstructured":"Leppik, L. et al. Profiling of amino acids and their derivatives biogenic amines before and after antipsychotic treatment in first-episode psychosis. Front. Psychiatry 9, 155 (2018).","journal-title":"Front. Psychiatry"},{"key":"71014_CR12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/456443c","volume":"456","author":"AK Arakaki","year":"2008","unstructured":"Arakaki, A. K., Skolnick, J. & McDonald, J. F. Marker metabolites can be therapeutic targets as well. Nature 456, 443\u2013443 (2008).","journal-title":"Nature"},{"key":"71014_CR13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1017\/S1092852918000962","volume":"24","author":"HO Tayeb","year":"2019","unstructured":"Tayeb, H. O., Murad, H. A., Rafeeq, M. M. & Tarazi, F. I. Pharmacotherapy of schizophrenia: toward a metabolomic-based approach. CNS Spectr. 24, 281\u2013286 (2019).","journal-title":"CNS Spectr."},{"key":"71014_CR14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fnins.2016.00331","volume":"10","author":"K Koido","year":"2016","unstructured":"Koido, K. et al. Taurine and epidermal growth factor belong to the signature of first-episode psychosis. Front. Neurosci. 10, 331 (2016).","journal-title":"Front. Neurosci."},{"key":"71014_CR15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/234107a0","volume":"234","author":"AN Davison","year":"1971","unstructured":"Davison, A. N. & Kaczmarek, L. K. Taurine - a possible neurotransmitter?. Nature 234, 107\u2013108 (1971).","journal-title":"Nature"},{"key":"71014_CR16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1152\/physrev.1993.73.1.119","volume":"73","author":"JA Sturman","year":"1993","unstructured":"Sturman, J. A. Taurine in development. Physiol. Rev. 73, 119\u2013147 (1993).","journal-title":"Physiol. Rev."},{"key":"71014_CR17","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/j.1471-4159.1988.tb01807.x","volume":"51","author":"JV Wade","year":"1988","unstructured":"Wade, J. V., Olson, J. P., Samson, F. E., Nelson, S. R. & Pazdernik, T. L. A possible role for taurine in osmoregulation within the brain. J. Neurochem. 51, 740\u2013745 (1988).","journal-title":"J. Neurochem."},{"key":"71014_CR18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02069502","volume":"11","author":"SS Oja","year":"1996","unstructured":"Oja, S. S. & Saransaari, P. Taurine as osmoregulator and neuromodulator in the brain. Metab. Brain Dis. 11, 153\u2013164 (1996).","journal-title":"Metab. Brain Dis."},{"key":"71014_CR19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/jnr.490330117","volume":"33","author":"MR Quinn","year":"1992","unstructured":"Quinn, M. R. & Miller, C. L. Taurine allosterically modulates flunitrazepam binding to synaptic membranes. J. Neurosci. Res. 33, 136\u2013141 (1992).","journal-title":"J. Neurosci. Res."},{"key":"71014_CR20","doi-asserted-by":"crossref","first-page":"9459","DOI":"10.1523\/JNEUROSCI.19-21-09459.1999","volume":"19","author":"A El Idrissi","year":"1999","unstructured":"El Idrissi, A. & Trenkner, E. Growth factors and taurine protect against excitotoxicity by stabilizing calcium homeostasis and energy metabolism. J. Neurosci. 19, 9459\u20139468 (1999).","journal-title":"J. Neurosci."},{"key":"71014_CR21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-4684-3968-7_7","volume-title":"Regulatory mechanisms of synaptic transmission","author":"H Pasantes-Morales","year":"1981","unstructured":"Pasantes-Morales, H. & Mor\u00e1n, J. Taurine as a neuromodulator: its action on calcium fluxes and neurotransmitter release. In Regulatory mechanisms of synaptic transmission (eds Tapia, R. & Cotman, C. W.) 141\u2013154 (Springer, New York, 1981)."},{"key":"71014_CR22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-1-4614-6130-2_4","volume-title":"Taurine 8","author":"CY Chan","year":"2013","unstructured":"Chan, C. Y. et al. Direct interaction of taurine with the NMDA glutamate receptor subtype via multiple mechanisms. In Taurine 8 (eds El Idrissi, A. & L\u2019Amoreaux, W. J.) 45\u201352 (Springer, New York, 2013)."},{"key":"71014_CR23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0014-2999(95)00224-9","volume":"281","author":"H-Q Wu","year":"1995","unstructured":"Wu, H.-Q., Ungerstedt, U. & Schwarcz, R. l-\u03b1-Aminoadipic acid as a regulator of kynurenic acid production in the hippocampus: a microdialysis study in freely moving rats. Eur. J. Pharmacol. 281, 55\u201361 (1995).","journal-title":"Eur. J. Pharmacol."},{"key":"71014_CR24","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1172\/JCI64801","volume":"123","author":"TJ Wang","year":"2013","unstructured":"Wang, T. J. et al. 2-Aminoadipic acid is a biomarker for diabetes risk. J. Clin. Invest. 123, 4309\u20134317 (2013).","journal-title":"J. Clin. Invest."},{"key":"71014_CR25","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1021\/pr300459d","volume":"11","author":"H-L Cai","year":"2012","unstructured":"Cai, H.-L. et al. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-na\u00efve schizophrenia patients after treatment with risperidone. J. Proteome Res. 11, 4338\u20134350 (2012).","journal-title":"J. Proteome Res."},{"key":"71014_CR26","doi-asserted-by":"crossref","first-page":"22127","DOI":"10.1002\/syn.22127","volume":"73","author":"B Garip","year":"2019","unstructured":"Garip, B. & Kayir, H. Alteration in NMDAR-related amino acids in first episode psychosis. Synapse 73, 22127 (2019).","journal-title":"Synapse"},{"key":"71014_CR27","volume-title":"Disorders of proline and hydroxyproline metabolism. Metabolic and molecular basis of inherited disease 1821\u20131838","author":"JM Phang","year":"2004","unstructured":"Phang, J. M., Hu, C. A. & Valle, D. Disorders of proline and hydroxyproline metabolism. Metabolic and molecular basis of inherited disease 1821\u20131838 (McGraw-Hill Press, New York, 2004)."},{"key":"71014_CR28","first-page":"793","volume":"41","author":"V Henzi","year":"1992","unstructured":"Henzi, V., Reichling, D. B., Helm, S. W. & MacDermott, A. B. L-proline activates glutamate and glycine receptors in cultured rat dorsal horn neurons. Mol. Pharmacol. 41, 793\u2013801 (1992).","journal-title":"Mol. Pharmacol."},{"key":"71014_CR29","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.tins.2016.10.009","volume":"39","author":"DW Volk","year":"2016","unstructured":"Volk, D. W., Gonzalez-Burgos, G. & Lewis, D. A. l -Proline, GABA synthesis and gamma oscillations in schizophrenia. Trends Neurosci. 39, 797\u2013798 (2016).","journal-title":"Trends Neurosci."},{"key":"71014_CR30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","volume":"511","author":"S Ripke","year":"2014","unstructured":"Ripke, S. et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421\u2013427 (2014).","journal-title":"Nature"},{"key":"71014_CR31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0920-9964(94)00080-R","volume":"14","author":"J Wei","year":"1995","unstructured":"Wei, J. Low concentrations of serum tyrosine in neuroleptic-free schizophrenics with an early onset. Schizophr. Res. 14, 257\u2013260 (1995).","journal-title":"Schizophr. Res."},{"key":"71014_CR32","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00431-002-1126-2","volume":"162","author":"A B\u00e9langer-Quintana","year":"2003","unstructured":"B\u00e9langer-Quintana, A. et al. Hyperammonaemia as a cause of psychosis in an adolescent. Eur. J. Pediatr. 162, 773\u2013775 (2003).","journal-title":"Eur. J. Pediatr."},{"key":"71014_CR33","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison, D. B. et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156, 1686\u20131696 (1999).","journal-title":"Am. J. Psychiatry"},{"key":"71014_CR34","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht, S. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet 382, 951\u2013962 (2013).","journal-title":"The Lancet"},{"key":"71014_CR35","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MED.0b013e32833de61c","volume":"17","author":"P Pramyothin","year":"2010","unstructured":"Pramyothin, P. & Khaodhiar, L. Metabolic syndrome with the atypical antipsychotics . Curr. Opin. Endocrinol. Diabetes Obes. 17, 460\u2013466 (2010).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"71014_CR36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3389\/fnins.2017.00741","volume":"11","author":"AT Raben","year":"2018","unstructured":"Raben, A. T. et al. The complex relationship between antipsychotic-induced weight gain and therapeutic benefits: a systematic review and implications for treatment. Front. Neurosci. 11, 741 (2018).","journal-title":"Front. Neurosci."},{"key":"71014_CR37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fnins.2017.00643","volume":"11","author":"J Chen","year":"2017","unstructured":"Chen, J., Huang, X.-F., Shao, R., Chen, C. & Deng, C. Molecular mechanisms of antipsychotic drug-induced diabetes. Front. Neurosci. 11, 643 (2017).","journal-title":"Front. Neurosci."},{"key":"71014_CR38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12916-019-1346-1","volume":"17","author":"T Bretler","year":"2019","unstructured":"Bretler, T., Weisberg, H., Koren, O. & Neuman, H. The effects of antipsychotic medications on microbiome and weight gain in children and adolescents. BMC Med. 17, 112 (2019).","journal-title":"BMC Med."},{"key":"71014_CR39","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1124\/mol.104.008185","volume":"67","author":"PE Chen","year":"2005","unstructured":"Chen, P. E. et al. Structural features of the glutamate binding site in recombinant NR1\/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling. Mol. Pharmacol. 67, 1470\u20131484 (2005).","journal-title":"Mol. Pharmacol."},{"key":"71014_CR40","unstructured":"Concise encyclopedia biochemistry and molecular biology. (Walter de Gruyter, 1997)."},{"key":"71014_CR41","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/bjsm.2007.040378","volume":"42","author":"A Bassini-Cameron","year":"2008","unstructured":"Bassini-Cameron, A., Monteiro, A., Gomes, A., Werneck-de-Castro, J. P. S. & Cameron, L. Glutamine protects against increases in blood ammonia in football players in an exercise intensity-dependent way. Br. J. Sports Med. 42, 260\u2013266 (2008).","journal-title":"Br. J. Sports Med."},{"key":"71014_CR42","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/jcp.20339","volume":"204","author":"R Curi","year":"2005","unstructured":"Curi, R. et al. Molecular mechanisms of glutamine action. J. Cell. Physiol. 204, 392\u2013401 (2005).","journal-title":"J. Cell. Physiol."},{"key":"71014_CR43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/nu10020140","volume":"10","author":"J Liu","year":"2018","unstructured":"Liu, J., Lkhagva, E., Chung, H.-J., Kim, H.-J. & Hong, S.-T. The pharmabiotic approach to treat hyperammonemia. Nutrients 10, 140 (2018).","journal-title":"Nutrients"},{"key":"71014_CR44","doi-asserted-by":"crossref","first-page":"057006","DOI":"10.1117\/1.JBO.20.5.057006","volume":"20","author":"C Popa","year":"2015","unstructured":"Popa, C., Petrus, M. & Bratu, A. M. Ammonia and ethylene biomarkers in the respiration of the people with schizophrenia using photoacoustic spectroscopy. J. Biomed. Opt. 20, 057006 (2015).","journal-title":"J. Biomed. Opt."},{"key":"71014_CR45","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.psychres.2013.09.014","volume":"210","author":"M Samuelsson","year":"2013","unstructured":"Samuelsson, M., Skogh, E., Lundberg, K., Vrethem, M. & \u00d6llinger, K. Taurine and glutathione in plasma and cerebrospinal fluid in olanzapine treated patients with schizophrenia. Psychiatry Res. 210, 819\u2013824 (2013).","journal-title":"Psychiatry Res."},{"key":"71014_CR46","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/j.neuroimage.2009.10.031","volume":"49","author":"Y Shirayama","year":"2010","unstructured":"Shirayama, Y. et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. NeuroImage 49, 2783\u20132790 (2010).","journal-title":"NeuroImage"},{"key":"71014_CR47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4239\/wjd.v8.i8.390","volume":"8","author":"A Annamalai","year":"2017","unstructured":"Annamalai, A., Kosir, U. & Tek, C. Prevalence of obesity and diabetes in patients with schizophrenia. World J. Diabetes 8, 390 (2017).","journal-title":"World J. Diabetes"},{"key":"71014_CR48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/157339907781368940","volume":"3","author":"S-J Kim","year":"2007","unstructured":"Kim, S.-J., Gupta, R. C. & Lee, H. W. Taurine-diabetes interaction: from involvement to protection. Curr. Diabetes Rev. 3, 165\u2013175 (2007).","journal-title":"Curr. Diabetes Rev."},{"key":"71014_CR49","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00394-013-0586-7","volume":"53","author":"FT Rosa","year":"2014","unstructured":"Rosa, F. T., Freitas, E. C., Deminice, R., Jord\u00e3o, A. A. & Marchini, J. S. Oxidative stress and inflammation in obesity after taurine supplementation: a double-blind, placebo-controlled study. Eur. J. Nutr. 53, 823\u2013830 (2014).","journal-title":"Eur. J. Nutr."},{"key":"71014_CR50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.31887\/DCNS.2014.16.3\/aguidotti","volume":"16","author":"A Guidotti","year":"2014","unstructured":"Guidotti, A. & Grayson, D. R. DNA methylation and demethylation as targets for antipsychotic therapy. Dialogues Clin. Neurosci. 16, 419\u2013429 (2014).","journal-title":"Dialogues Clin. Neurosci."},{"key":"71014_CR51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0014-2999(88)90367-6","volume":"154","author":"PJ Birch","year":"1988","unstructured":"Birch, P. J., Grossman, C. J. & Hayes, A. G. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur. J. Pharmacol. 154, 85\u201387 (1988).","journal-title":"Eur. J. Pharmacol."},{"key":"71014_CR52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fmolb.2019.00007","volume":"6","author":"F Rossi","year":"2019","unstructured":"Rossi, F., Miggiano, R., Ferraris, D. M. & Rizzi, M. The synthesis of kynurenic acid in mammals: an updated kynurenine aminotransferase structural KATalogue. Front. Mol. Biosci. 6, 7 (2019).","journal-title":"Front. Mol. Biosci."},{"key":"71014_CR53","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fnins.2015.00372","volume":"9","author":"N M\u00fcller","year":"2015","unstructured":"M\u00fcller, N., Weidinger, E., Leitner, B. & Schwarz, M. J. The role of inflammation in schizophrenia. Front. Neurosci. 9, 372 (2015).","journal-title":"Front. Neurosci."},{"key":"71014_CR54","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00702-018-1838-8","volume":"125","author":"HPG Joaquim","year":"2018","unstructured":"Joaquim, H. P. G., Costa, A. C., Gattaz, W. F. & Talib, L. L. Kynurenine is correlated with IL-1\u03b2 in plasma of schizophrenia patients. J. Neural Transm. 125, 869\u2013873 (2018).","journal-title":"J. Neural Transm."},{"key":"71014_CR55","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1017\/S1461145710001689","volume":"14","author":"R Condray","year":"2011","unstructured":"Condray, R. et al. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int. J. Neuropsychopharmacol. 14, 756\u2013767 (2011).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"71014_CR56","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ejps.2017.05.018","volume":"109","author":"I Kohler","year":"2017","unstructured":"Kohler, I., Hankemeier, T., van der Graaf, P. H., Knibbe, C. A. J. & van Hasselt, J. G. C. Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine. Eur. J. Pharm. Sci. 109, S15\u2013S21 (2017).","journal-title":"Eur. J. Pharm. Sci."},{"key":"71014_CR57","volume-title":"The ICD\u201310 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines","author":"World Health Organization","year":"1992","unstructured":"World Health Organization. The ICD\u201310 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines (Switzerland, Geneva, 1992)."},{"key":"71014_CR58","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall, J. E. & Gorham, D. R. The brief psychiatric rating scale. Psychol. Rep. 10, 799\u2013812 (1962).","journal-title":"Psychol. Rep."},{"key":"71014_CR59","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cca.2016.01.026","volume":"455","author":"S Takehana","year":"2016","unstructured":"Takehana, S. et al. The effects of pre-analysis sample handling on human plasma amino acid concentrations. Clin. Chim. Acta 455, 68\u201374 (2016).","journal-title":"Clin. Chim. Acta"},{"key":"71014_CR60","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1021\/acs.jproteome.7b00518","volume":"17","author":"M Haid","year":"2018","unstructured":"Haid, M. et al. Long-term stability of human plasma metabolites during storage at \u221280 \u00b0C. J. Proteome Res. 17, 203\u2013211 (2018).","journal-title":"J. Proteome Res."},{"key":"71014_CR61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.conctc.2018.03.008","volume":"10","author":"J Twisk","year":"2018","unstructured":"Twisk, J. et al. Different ways to estimate treatment effects in randomised controlled trials. Contemp. Clin. Trials Commun. 10, 80\u201385 (2018).","journal-title":"Contemp. Clin. Trials Commun."},{"key":"71014_CR62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"key":"71014_CR63","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2018","unstructured":"Core Team, R. R: a language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria, 2018)."},{"key":"71014_CR64","unstructured":"Pinheiro, J., Bates, D., DebRoy, S., Sarkar, D. & R Core Team. nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1-131.1 (2018). https:\/\/CRAN.R-project.org\/package=nlme."},{"key":"71014_CR65","volume-title":"Stata Statistical Software: Release 13","author":"StataCorp","year":"2011","unstructured":"StataCorp. Stata Statistical Software: Release 13 (StataCorp LP,\u00a0College Station, TX, 2013)."},{"key":"71014_CR66","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: elegant graphics for data analysis","author":"H Wickham","year":"2016","unstructured":"Wickham, H. ggplot2: elegant graphics for data analysis (Springer, Berlin, 2016)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71014-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71014-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71014-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T21:55:26Z","timestamp":1723413326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-71014-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,19]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["71014"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-71014-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,19]]},"assertion":[{"value":"21 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13983"}}